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Abstract
BACKGROUND—Animal studies have shown that high doses of caffeine might cause 
congenital limb deficiencies (LDs); however, no epidemiologic studies have explored this relation.
METHODS—This case-control study assessed associations between maternal dietary caffeine and 
congenital LDs using data from the National Birth Defects Prevention Study (NBDPS), with 844 
LD cases and 8069 controls from 1997 to 2007. Caffeine intakes from beverages (coffee, tea, and 
soda) and chocolate combined and by beverage type were examined. Adjusted odds ratios (aORs) 
and 95% confidence intervals (CIs) were estimated for subtypes of isolated LDs (no additional 
major anomalies) and LDs with other major anomalies separately, comparing the odds of 10 to 
<100, 100 to <200, 200 to <300, and 300+ mg/day total caffeine intake to 0 to <10 mg/day.
RESULTS—All total dietary caffeine intake categories of 10 mg/day and above were marginally 
associated with odds of all isolated LDs combined (aOR, 1.4–1.7), isolated longitudinal LDs 
(aOR, 1.2–1.6), and isolated transverse LDs (aOR, 1.3–1.8) compared to the lowest intake 
category. A dose-response pattern for total dietary caffeine intake was not observed.
CONCLUSIONS—A weak increased risk of congenital LDs associated with maternal dietary 
caffeine consumption was observed in this study; however, risk did not vary by amount of caffeine 
consumed.
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INTRODUCTION
Pregnant women in the United States are widely exposed to caffeine from consumption of 
coffee, soda, tea, and chocolate (Knight et al., 2004; Frary et al., 2005). Dietary caffeine is 
absorbed by the gastrointestinal tract and reaches almost all tissues of the body within 45 
minutes (Marks and Kelly, 1973). In healthy adult women, the half-life of caffeine is about 2 
to 6 hours (Patwardhan et al., 1980; Charles et al., 2008), which may be increased to 11 
hours among those taking oral contraceptives (Patwardhan et al., 1980) or who are pregnant 
(Knutti et al., 1982). Also, caffeine crosses the placenta but the enzymes necessary to 
metabolize caffeine are absent in the fetus until several days after birth (Weathersbee and 
Lodge, 1977).
In addition, animal models have shown a teratogenic effect of maternal caffeine intake at 
high doses (Fujii et al., 1969; Nishimura and Nakai, 1960; Scott, 1983). Limb deficiencies 
(LDs), along with cleft palate, and neural tube defects (NTDs) are among the most frequent 
congenital malformations induced in animals by caffeine doses of 100 to 200 mg/kg (Fujii et 
al., 1969; Scott, 1983; Moriguchi and Scott, 1986). Synergistic teratogenic effects of 
subteratogenic doses of caffeine with certain agents, such as acetazolamide, treatment for 
glaucoma, and seizures (Ritter et al., 1982; Beck and Urbano, 1991), or mitomycin C, a 
hemotherapeutic agent (Fujii and Nakatsuka, 1983), have been observed in rodents.
In adult humans, caffeine intake has been associated with increased plasma cholesterol and 
homocysteine levels. Increased maternal plasma cholesterol level may be related to 
development of congenital vascular disease (Manderson et al., 2002), and increased 
maternal homocysteine level has been associated with congenital heart defects (Wenstrom et 
al., 2001) and NTDs (Mills et al., 1995). Although the literature has generally indicated that 
dietary caffeine is likely to be a weak teratogen at most for humans (Nelson and Forfar, 
1971; Fedrick, 1974; Aro et al., 1982; Linn et al., 1982; Rosenberg et al., 1982; Kurppa et 
al., 1983; Furuhashi et al., 1985; Adams et al., 1989; Tikkanen and Heinonen, 1990; Olsen 
et al., 1991; Tikkanen and Heinonen, 1991; McDonald et al., 1992; Tikkanen and Heinonen, 
1992a; Tikkanen and Heinonen, 1992b; Werler et al., 1992; Ferencz et al., 1993; Tikkanen 
and Heinonen, 1994; Fixler and Threlkeld, 1998; Samrén et al., 1999; Torfs and 
Christianson, 1999; Torfs and Christianson, 2000; Browne, 2006; Browne et al., 2007; 
Miller, 2008; Mongraw–Chaffin et al., 2008; Collier et al., 2009; Schmidt et al., 2009), 
considering the common use of caffeine by pregnant women, a slight risk elevation could 
have a significant impact at the population level. Given that LDs are the most frequent 
malformations induced by caffeine exposure in some animal studies (Fujii et al., 1969; 
Scott, 1983; Moriguchi and Scott, 1986) and that this relationship between LDs and 
maternal caffeine consumption has not been examined in humans, the current study explored 
the association between maternal caffeine consumption and LDs.
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Lumping etiologically different groups of malformations together (Nelson and Forfar, 1971; 
Linn et al., 1982; Olsen et al., 1991) or into broad categories (Rosenberg et al., 1982; 
Kurppa et al., 1983; Furuhashi et al., 1985; McDonald et al., 1992; Samrén et al., 1999; 
Torfs and Christianson, 1999; Natsume et al., 2000) may have obscured identification of 
positive associations for a specific defect group. In addition, many studies assessed the 
dietary caffeine intake only from coffee and tea consumption.
This study attempts to address these limitations by measuring maternal caffeine intake from 
caffeinated coffee, tea, soda, and chocolate and by exploring the effect of caffeine exposure 
on the etiologically different subtypes of LDs using the National Birth Defects Prevention 
Study (NBDPS) data. Analyses previously conducted using NBPDS data examined 
associations between maternal dietary caffeine consumption and congenital heart defects 
(Browne et al., 2007), orofacial defects (Collier et al., 2009), NTDs (Schmidt et al., 2009), 
anorectal atresia (Miller et al., 2009), and bilateral renal agenesis or hypoplasia (Slickers et 
al., 2008), as well as other birth defect groups (Browne et al., 2011). The accumulated 
number of cases from NBDPS is now sufficient to examine subtypes of LDs. Potential effect 
modification by maternal smoking, alcohol consumption, and use of vasoconstrictive 
medication was also evaluated.
MATERIALS AND METHODS
Study Population
The study population included participants in the NBDPS with estimated date of delivery 
(EDD) from October 1997 through December 2007. The NBDPS is an ongoing multisite, 
population-based case-control study of infants with one or more of 37 different types of 
major structural defects, excluding infants with defects attributed to a known chromosomal 
or single-gene abnormality (Yoon et al., 2001). Cases are identified by the existing birth 
defect surveillance system of each participating site (Arkansas, California, Georgia [CDC], 
Iowa, Massachusetts, New Jersey, New York, North Carolina, Texas, and Utah) and must 
have been diagnosed with at least one major, eligible birth defect within the first year of life, 
as described elsewhere (Rasmussen et al., 2003). Live births were included in all study sites 
throughout the study period. Fetal deaths and elective terminations were recorded by some 
sites during the whole or part of the study period. Details are described elsewhere (State 
birth defects surveillance program directly, 2000; State birth defects surveillance program 
directory, 2007). Controls were live born infants without birth defects randomly selected 
from birth certificates (Iowa, Massachusetts, New Jersey, North Carolina, and Utah) or 
hospitals (California, New York, and Texas) (Cogswell et al., 2009) from the same time 
period and geographic region as case infants. Participation rates for limb deficiency cases 
and control infants were 69% and 65%, respectively.
The current analysis included case infants (live births from 10 study sites, stillbirths from 9 
study sites, and elected terminations from 6 study sites) with a diagnosis of an LD. Eligible 
LDs were (1) absent or partially absent bony elements of the extremities, diagnosed by 
radiography or reliable physical examination or (2) diagnoses of split hand/split foot if there 
was a ‘‘deep cleft’’ in the hand or foot. Ineligible LD diagnoses were: (1) generalized limb 
shortening without confirmation or absent bones; (2) brachydactyly types A–E; (3) known 
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or strongly suspected single gene conditions or chromosome abnormalities; (4) unconfirmed 
LD diagnoses; (5) deficiencies related to twinning such as acephalus-acardia; (6) 
sirenomelia; and (7) limb-body wall and amniotic band phenotypes.
Because LDs are often associated with other birth defects (Sadler, 2009) and the presence of 
additional defects might reflect the underlying mechanism(s) of a teratogen (Holmes, 2002), 
the study included LD cases with and without an additional major nonlimb anomaly. Case 
deliveries were classified as an isolated LD if they had no major nonlimb anomaly 
(Rasmussen et al., 2003), although an isolated LD case could have a defect in more than one 
limb. Cases with one or more major unrelated nonlimb anomalies were classified as a 
multiple congenital anomaly (MCA) cases with LDs. The multivariable analysis was 
conducted separately for isolated LD cases and MCA LD cases. The subtypes of the eligible 
LDs were longitudinal LDs, transverse LDs, intercalary LDs, and not otherwise specified 
LDs. Longitudinal LDs include two major subtypes, preaxial longitudinal LDs and postaxial 
longitudinal LDs. Preaxial LDs have a higher prevalence than postaxial LDs, and the two 
subtypes might have different etiologies (Holmes, 2011). With adequate number of cases, 
our analysis was able to include preaxial LD subtype as a separate case group. The analysis 
only included subtypes with 100 or more cases.
Exclusion Criteria
Information on maternal caffeine exposure from dietary sources and medication, as well as 
maternal demographic characteristics and health history was collected using a maternal 
telephone interview administered in English or Spanish language. Case and control mothers 
who did not speak English or Spanish were excluded. Interviews were completed between 6 
weeks and 24 months after EDD of the LD case or control infant.
Maternal type 1 or type 2 diabetes is a known risk factor for many birth defects, including 
LDs (Aberg et al., 2001). Because very small percentages of mothers (3.0% of case mothers 
and 0.6% of control mothers) were diagnosed with type 1 or type 2 diabetes before 
pregnancy, births with maternal history of type 1 or type 2 diabetes diagnosed before 
conception were excluded from the analysis. Infants whose mother had chorionic villus 
sampling during pregnancy were also excluded because this procedure has been associated 
with an increased risk for LDs (Holmes, 2002) (3.8% of case mothers and 2.8% of control 
mothers).
Exposure Assignment
Total dietary caffeine intake was defined as the sum of the estimated average daily intake of 
caffeine from caffeinated coffee, non-herbal tea, soda, and chocolate during the year before 
the index pregnancy. For coffee and tea, mothers were asked ‘How many cups of caffeinated 
or regular (coffee/tea) did you usually drink?’ Information was not collected on 
consumption of decaffeinated coffee or tea. For soda consumption, mothers were asked 
about the brands they usually drank, the frequency (per month) of consumption, and whether 
the soda consumed were diet or caffeine free. Mothers were also asked if the consumption of 
coffee, tea, or soda increased, decreased, or maintained the same during pregnancy 
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compared to their reported consumption during the year before pregnancy. Caffeine intake 
was examined from all sources combined and for each beverage type separately.
The caffeine contents assignment was based on previous literature (Bracken et al., 2002; 
Browne et al., 2007; Schmidt et al., 2009). The study used the estimate from Bracken 
(Bracken et al., 2002) of 100 mg caffeine for a cup of coffee and 37 mg caffeine for each 
cup of tea. Brand-specific caffeine contents for soda were based on the caffeine content per 
12 ounce serving obtained from soda manufacturers (Schmidt, 2007; Schmidt et al., 2009). 
An average value of 37 mg was assigned to caffeinated soda for which caffeine was an 
ingredient but the amount could not be determined, based on a review of manufacturers 
provided information (Schmidt, 2007). A weighted average of 10 mg per ounce was used for 
chocolate (National Confectioners Association, 2009).
Consistent with previous literature (Browne et al., 2011; Collier et al., 2009; Schmidt et al., 
2009), total caffeine consumption was classified as <10 mg/day, 10 to <100 mg/day, 100 to 
<200 mg/day, 200 to <300 mg/ day, and ≥300 mg/day. Coffee consumption was classified 
as <1 cup/month, 1 cup/month to 6 cups/week, 1 cup/day, 2 cups/day, and ≥3 cups/day for 
coffee consumption. Tea consumption was classified as <1 cup/ month, 1 cup/month to 6 
cups/week, 1 to 2 cups/day, and ≥3 cups/day. Given that soda consumption was estimated 
combining reported consumption frequencies and brand-specific caffeine content, the soda 
consumption for the analysis was classified as 0, <34 mg/day, 34 to <102 mg/day, and ≥102 
mg/day (caffeinated sodas generally contain 34+ mg of caffeine, we used 34 as the cut-point 
to approximate <1 servings, 1–2 servings, and 3 or more servings per day).
The lowest caffeine intake categories (0–10 mg/day for total caffeine intake, 0–<1 cup/
month for coffee consumption, 0–<1 cup/month for tea consumption, and 0–<1 12 ounce 
serving/month for soda consumption) were used as the reference group when evaluating the 
crude and adjusted associations between maternal caffeine exposure and LD.
The Slone Epidemiology Center Drug Dictionary (Slone Epidemiology Center at Boston 
University, Boston, MA) was used to identify caffeine-containing medications reported 
during the maternal interview. This source of exposure was not further analyzed as a major 
source of caffeine because only 1% of the study participants had maternal exposure to 
medications with caffeine.
Potential Confounders and Effect Modifiers
Maternal and pregnancy characteristics were examined as potential confounders and effect 
modifiers. Maternal characteristics examined were: age at conception (<20 years, 20–34 
years, or ≥35 years), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, or 
other), education (≤12 years or >12 years), body mass index (<18.5, 18.5–<25, or ≥25), 
parity (0 or ≥1 live births), initiation of prenatal care (first trimester, second trimester, or 
third trimester), gestational diabetes (yes or no), nausea or vomiting during the first month 
of pregnancy (yes or no), fever in the first trimester (yes or no), and study site. 
Periconceptional exposures examined for the period 1 month before pregnancy through the 
first trimester included: cigarette smoking (none, environmental smoking exposure only, or 
active smoking with or without environmental smoking exposure), smoking frequency 
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(none, <1 pack/day, or ≥1 pack/day), alcohol consumption (yes or no), alcohol consumption 
frequency (none, <1 drink/day, or ≥1 drink/day), binge drinking (no drinking, drink but not 
binge drinking, or ≥4 drinks/occasion), oral contraception use (yes or no), use of 
vasoconstrictive medicine including decongestants, ergot anti-migraine medications, 
amphetamines, and cocaine (yes or no), and use of folic acid-containing supplements during 
1 month before pregnancy through the first month of gestation was also considered (yes or 
no). Illicit drug use was not analyzed separately because <1% of study participants reported 
any maternal use during 1 month before pregnancy through the first trimester.
Data Analysis
The study examined the association between total dietary caffeine intake and LDs, and the 
independent associations between coffee, tea, and soda consumption and LDs. Bivariable 
and stratified analyses were conducted to identify potential confounders and effect 
modifiers. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to 
estimate the associations between caffeine intake and LDs, and between maternal 
characteristics and LDs.
Crude caffeine-LD ORs were further stratified by selected maternal exposures, specifically 
smoking, alcohol, and vasoconstrictive medicines. The rationales were that smoking might 
modify caffeine metabolism (Parsons and Neims, 1978; Vistisen et al., 1992; Wilson, 2004), 
and caffeine exposure might enhance teratogenicity of substances such as nicotine, alcohol, 
bronchodilators, and antiseizure medication in some animal studies (Nehlig and Debry, 
1994), and that limb development might be influenced through vascular disruption (Van 
Allen, 1981). Additive interactions (risk-difference modification) were assessed using 
relative excess risk due to interaction (RERI) described by Rothman et al. (2008). The 
statistical test of RERI used the bootstrapping method developed by Knol et al. (2011).
Logistic regression models were computed to estimate ORs and 95% CIs for the association 
between LDs and maternal caffeine intake. Separate logistic regression models were 
estimated for each LD subtype with total maternal dietary caffeine intake, and for each 
combination of LD subtype and intake of coffee, tea, or soda. Model building started from a 
full model containing all the potential confounders identified from the bivariable analysis. If 
removing a variable resulted in a <10% change in caffeine exposure effect, and if the 
removal did not change the model fit significantly by the log-likelihood ratio test (Akaike, 
1974), the variable was removed from the model. The Hosmer and Lemeshow test was used 
to assess the goodness-of-fit (Hosmer and Lemeshow, 2000). The above model construction 
was conducted for isolated cases and MCA cases separately.
Sensitivity analyses were conducted to assess the impact of exposure misclassification using 
the method described by Greenland and Rothman (2008). A subanalysis was conducted 
restricted to those mothers who completed the interview within 12 months after the EDD of 
the infant to limit potential recall bias. Another subanalysis excluded the mothers taking any 
caffeine-contained medication to avoid the potential confounding effect of caffeine in 
medication. Because a substantial proportion of women decreased their consumption of 
coffee, tea, or soda during pregnancy, which might be related to birth planning or early 
recognition of pregnancy, the analysis also compared the results among mothers who had 
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early recognition of pregnancy, planned pregnancy, or nausea or vomiting during early 
pregnancy to those who did not meet these conditions. All analyses were conducted using 
SAS software, version 9.1 (SAS Institute, Cary, NC).
RESULTS
During the study period, 23,306 case and 8488 control infants were enrolled in the NBDPS. 
Among all case infants, 920 were identified with LDs, which included 871 live births, 19 
stillbirths, and 30 induced abortions. After excluding infants with amniotic band syndrome 
(3 cases), LD case and control infants missing maternal caffeine exposure information (11 
cases and 141 controls), mothers reported to have had chorionic villus sampling procedures 
during the index pregnancy (35 cases and 234 controls), and mothers diagnosed with type 1 
or type 2 diabetes before pregnancy (28 cases and 51 controls), 844 LD cases and 8069 
control infants remained.
As shown in Table 1, the LD subtypes with the largest numbers were transverse, 
longitudinal, and preaxial, of which 85%, 55%, and 38% were isolated LD cases, 
respectively.
Table 2 presents the distribution of maternal and pregnancy characteristics of the study 
participants. A larger proportion of case infants were boys compared to control infants. 
Compared to the control mothers, a higher proportion of case mothers tended to be younger 
in age and not to have children before the index pregnancy, to be of Hispanic ethnicity, to 
have 12 years of education or less, and to be overweight or obese. Case mothers were less 
likely to report nausea or vomiting during the first month compared to control mothers. 
Fever during pregnancy, active periconceptional smoking, and vasoconstrictive medication 
use were more common among case mothers compared to control mothers. Alcohol 
drinking, including binge drinking, was less often reported among case mothers compared to 
control mothers. Folic acid supplement use was slightly more common among mothers of all 
LD subtypes, except transverse LD subtype, compared to control mothers.
Among all eligible control mothers, 97% (n = 7806) reported caffeine consumption, with a 
mean intake of 129.4 mg/day. Of those control mothers who reported caffeine consumption, 
47% reported coffee consumption, 48% reported tea consumption, and 68% reported soda 
consumption, with mean caffeine intakes of 139.5 mg/day, 34.0 mg/day, and 64.7 mg/day, 
respectively. Among mothers of infants with LDs, 96% consumed dietary caffeine (data not 
shown).
The associations between maternal caffeine consumption and odds of each LD subtype were 
adjusted for 0, 1, or 2 confounders, depending on the subtype. Including all three beverage 
types together produced very similar results to the models with individual beverages, 
indicating that exposure sources did not act as confounders to each other. Therefore, the 
final models presented only included the individual beverage type of interest. No covariables 
were adjusted for in the final model of isolated longitudinal LDs, for which crude ORs were 
reported. ORs are presented in Table 3 by LD subtype for isolated cases and in Table 4 for 
MCA LD cases for total dietary caffeine, coffee, tea, and soda consumption.
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Increased odds for all isolated LDs combined and for isolated transverse LDs were observed 
for all total dietary caffeine intake categories compared to the referent category (Table 3). 
ORs were weakly to moderately elevated for all total daily dietary caffeine categories and 
isolated longitudinal LDs. Odds of isolated preaxial LDs were not associated with any 
caffeine consumption category compared to the no to low consumption category. No pattern 
of dose response was observed for any isolated LD subtype.
Coffee and tea consumptions were not associated with increased odds of any isolated LD 
subtype (Table 3). Tea consumption at 1 cup/month to 6 cups/week and 1 to 2 cups/day were 
inversely related to the odds of isolated longitudinal LDs (adjusted odds ratios [ORs], 0.6). 
Soda consumption was moderately associated with all isolated LDs (aORs, 1.2–1.4). The 
OR was marginally statistically significantly elevated for the association between isolated 
longitudinal LDs (aOR, 1.6; 95% CI, 1.0–2.5) and three or more servings of soda per day.
None of the MCA LD subtypes were associated with total caffeine, coffee, or tea 
consumption, except that consumption of 1 or 2 cups of coffee per day was marginally 
associated with decreased odds of MCA with longitudinal LDs and 1 cup per day was 
marginally associated with MCA with preaxial LDs compared to the referent (Table 4).
Odds of MCA with longitudinal LDs and MCA with preaxial LDs were elevated with soda 
consumption of 1 serving/month to <1 serving/day and 1 to 2 servings/day, with similar 
magnitudes between the two exposure categories (Table 4). However, the ORs decreased for 
the three or more servings/day category. Similarly, odds of MCA with transverse LDs were 
elevated among the 1 serving/month to < 1 serving/day (OR, 1.5; 95% CI, 0.8–2.6) soda 
consumption category, and then decreased in the higher exposure categories (Table 4).
To assess additive interaction for active maternal smoking, LD cases and control infants 
whose mothers were nonsmokers and had no to little dietary caffeine intake (0–<10 mg/day) 
served as the reference group. Compared to the reference group, the ORs across caffeine 
levels were similar among smoking and nonsmoking mothers. A pattern of less than additive 
interaction for caffeine consumption and active maternal smoking was observed for all 
isolated LDs combined, isolated transverse LDs, and all MCA LDs combined (Table 5). The 
ORs for smoking only (mothers who smoked and consumed little or no caffeine) were 
higher than the ORs for smoking and caffeine consumption for all intake categories. 
However, the RERI were not statistically significant. We did not observe additive 
interaction for environmental smoking exposure; neither did we observe effect modification 
for maternal alcohol consumption or vasoconstrictive medication after investigation.
Patterns of associations were not different from the main analyses when the analyses were 
restricted to mothers who completed the interview within 12 months of EDD (25 cases and 
663 controls), or mothers reported no caffeine contained medication use (833 cases and 
7966 controls). The results were also not different between those who had early recognition 
of pregnancy, planned pregnancy, or nausea/vomiting during early pregnancy (818 cases and 
7890 controls) and those who did not meet those criteria (26 cases and 179 controls) (data 
not shown).
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Results of the current study showed that maternal consumption of dietary caffeine was 
associated with a weak to moderate increased risk for all isolated LDs combined, isolated 
longitudinal LDs, and isolated transverse LDs. An elevated OR was observed for high soda 
consumption and isolated longitudinal LDs. The associations for isolated preaxial LD 
subtype were closer to the null compared to isolated longitudinal LDs. Coffee and tea 
consumption were not associated with any LD subtype. We did not observe a pattern of dose 
response for total dietary caffeine intake or for soda consumption. The observed results had 
no comparison to previous literature because no previous human epidemiology studies have 
examined caffeine and limb defects.
We suspected that maternal smoking might modify the effect of caffeine because smoking 
significantly increases the rate of caffeine metabolism by inducing CYP1A2 (Parsons and 
Neims, 1978; Vistisen et al., 1992). In our study, smoking and consuming caffeine together 
resulted in a lower risk than the sum of the risk for caffeine consumption alone and smoking 
alone. However, the ORs were similar across all levels of caffeine among both smokers and 
nonsmokers, and a higher OR was observed only for smokers who consumed little to no 
caffeine. Given that smoking status is often correlated with caffeine consumption, relatively 
few mothers smoked but consumed little to no caffeine and may differ with regard to 
potential confounding characteristics. Therefore, unmeasured or residual confounding and 
chance may have influenced the observed associations.
About 18% of women have total average caffeine intake of <10 mg per day (the referent 
group), meaning that on most days they drink no caffeinated coffee, caffeinated tea, or 
caffeinated sodas. It is possible that these women who avoid caffeine have healthier diets in 
terms of fruits and vegetables. That might explain the elevated ORs for those who have 
more usual intake of caffeine.
Besides estimating the dietary caffeine in mg/day, we categorized the frequency of 
consumption of coffee, tea, and soda and conducted the beverage-specific analyses to 
evaluate whether it was caffeine or other components in those beverages that might be 
playing a role in any observed associations. The association with soda and LDs is worth 
noting given the lack of association for coffee or tea. It might be explained by other 
constituents in these beverages, such as antioxidants present in coffee and tea that may be 
protective and that the sugar present in sodas may increase risk.
An important concern in this study is potential nondifferential error in the classification of 
caffeine consumption. The NBDPS measured caffeine intake in the year before pregnancy to 
better represent the actual exposure during the critical period of organogenesis (third–eighth 
weeks). According to previous studies, a large proportion of women change their caffeine 
consumption after pregnancy recognition or as the result of nausea or vomiting (Lawson et 
al., 2002), either of which can happen after limb development starts (Bayley et al., 2002). 
Retrospective assessment of women’s consumption in the first trimester may reflect that 
changed pattern of consumption. Caffeine intake in the year before pregnancy was 
considered to represent intake during the critical period which is the fourth to fifth 
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gestational week (Sadler, 2009); however, women might start to change or stop their 
caffeine intake sometime before conception due to pregnancy planning or for other reasons. 
In such cases, the caffeine intake in the year before pregnancy might not reflect the actual 
consumption during the target period. We assessed this source of potential misclassification 
by comparing results for mothers who recognized pregnancy early, had an intended 
pregnancy, or reported nausea or vomiting in the first gestational month to those for mothers 
who did not meet these conditions. The results of the stratified analysis were not 
significantly different from the primary analysis.
Another source of potential misclassification is the estimation of caffeine dose. The actual 
caffeine content was not measured directly in our analysis. Instead, standardized caffeine 
content was assigned to each unit size of coffee, tea, soda, and chocolate based on 
previously published guidelines. However, each serving of the beverage might differ widely 
in caffeine level or dose of intake. For example, caffeine levels in each cup of coffee may 
vary by brand, type of coffee bean, brewing time and method, serving size, seasonal 
variation of intake, or patterns of intake.
A complication with the soda classification concerns the reporting of energy drink 
consumption, which has increased in recent years (Reissig et al., 2009). These drinks were 
recorded in response to a question about consumption of sodas or soft drinks in the maternal 
interview for the years of this analysis. Women were not prompted to include energy drinks 
when they were asked to provide frequency of soda consumption, therefore, if women did 
not think to report energy drinks as sodas or soft drinks, misclassification of total caffeine 
intake occurred. With the growing energy drink market (Reissig et al., 2009), it will be of 
interest to ask specifically about energy drink consumption to ensure adequate recording of 
caffeine from this source.
The study did not observe a dose-response either for total caffeine intake or for the 
individual caffeinated beverages. Due to the potential misclassification of caffeine levels, 
the lack of a dose-response relation for elevated LD risk with increasing total caffeine intake 
should be interpreted with caution. Theoretically, a ‘dose-response fallacy’ (Selevan and 
Lemasters, 1987) may exist if a very high dose of caffeine exposure caused infertility or 
early fetal loss, resulting in that the lower dose of exposure was observed among the fetuses 
that survived to delivery. Without complete data on early loss and termination from all 
centers, it is possible that, if congenital anomalies within these outcome categories are 
related to high doses of caffeine, we may have missed associations for high caffeine 
consumption and LDs. However, results of animal studies did not show increased risk of 
embryonic death associated with oral administration of caffeine (Brent et al., 2011). We 
were not able to conduct separate analysis of postaxial or split hand/foot due to small 
numbers.
Recall bias might occur if case parents underreported or overreported exposures due to guilt 
or concern. Given that March of Dimes recommendations are to not consume more than 200 
mg/day of coffee (or caffeinated beverages) during pregnancy (March of Dimes, 2011), case 
mothers might be less likely to report consuming over 2 cups/day, which could be another 
explanation for no observed dose-response.
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The NBDPS reported a slightly higher response rate among cases versus controls (Cogswell 
et al., 2009). Case and control parents may have different motives for participating in the 
study; however, the possibility that participation was associated with caffeine intake seems 
small given that our control mothers had similar distributions for demographic 
characteristics compared to the base population (Cogswell et al., 2009).
In conclusion, the current study explored the effect of maternal dietary caffeine on the risk 
of congenital limb deficiencies overall, as well as in subtypes including longitudinal, 
preaxial longitudinal, and transverse limb deficiencies. We observed a moderate increase in 
the risk for limb deficiencies overall and for transverse LDs with maternal dietary caffeine 
consumption. Maternal soda consumption of one to two servings per day was associated 
with an elevated risk of MCA preaxial longitudinal LDs, and soda consumption of three or 
more servings per day was associated with elevated risk of isolated longitudinal LDs. No 
dose-response pattern was observed and no risk increase was observed for maternal coffee 
or tea consumption. Risk of isolated LDs overall, isolated transverse LD subtype, and MCA 
LDs overall associated with caffeine consumption above the lowest intake level among 
active tobacco smokers did not differ from that among nonsmokers. Future studies might 
improve exposure assessment by collecting more detailed information on change in 
consumption in early pregnancy, more accurately measuring caffeine contents in beverages, 
and measuring energy drink intake in addition to intake of soda and other soft drinks. 
Genetic epidemiologic studies including gene-caffeine and gene-gene interaction in the 
CYP1A2 and NAT2 genes would be of interest to further explore any relationship between 
caffeine and LDs.
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Table 1
LD Case Groups Included in Current Analysis, the NBDPS 1997 to 2007
All Isolated
LD case groups No. % No. %
All LDs 844 100 619 100
Longitudinal 324 38.4 178 28.8
Longitudinal preaxial 194 23.0 73 11.8
Transverse 488 57.8 413 66.7
Intercalary 39 4.6 33 5.3
Other 19 2.3 13 2.1
LD, limb deficiency; NBDPS, National Birth Defects Prevention Study.
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